Tyrosine-phosphorylated focal adhesion kinase (FAK) is required for the hypertrophic response of cardiomyocytes to growth factors and mechanical load, but the role of FAK serine phosphorylation in this process is unknown. The aims of the present study were to characterize FAK serine phosphorylation in cultured neonatal rat ventricular myocytes (NRVM), analyse its functional significance during hypertrophic signalling, and examine its potential role in the pathogenesis of human dilated cardiomyopathy (DCM).
Introduction
Cardiomyocytes adapt to increased haemodynamic load and growth factor stimulation by the addition and reorganization of their sarcomeres. An important site for new sarcomere formation is the costamere, which provides a physical coupling of the cardiomyocyte to its extracellular matrix, thereby linking the sarcolemmal membrane to peripheral Z-discs. 1 In cultured cardiomyocytes, costameres reorganize to form adhesive structures that are similar to typical focal adhesions found in non-muscle cells. 2 Because of the similarities between costamere formation in cardiomyocytes and focal adhesion formation in non-muscle cells, we and others have proposed that the non-receptor protein tyrosine kinase focal adhesion kinase (FAK) plays an important role in both processes. 3 FAK localizes to costameres in the intact heart in vivo, 4 and to focal adhesion sites and costameres in cultured cardiomyocytes. 5 Cardiomyocytes isolated from mice with tissue-specific deletion of FAK show increased length but not width and display disorganized myofibrils with increased non-myofibrillar space filled with swollen mitochondria. 6 FAK deletion also causes dilated cardiomyopathy (DCM) with ageing and produces eccentric rather than concentric left ventricular (LV) hypertrophy with angiotensin II (AngII) infusion or transverse aortic coarctation, suggesting an intrinsic abnormality in sarcomere assembly. 6 -8 Overexpression of FAK-related non-kinase (FRNK) or 'knocking-down' FAK by siRNA prevents normal costamerogenesis and myofibrillogenesis during skeletal muscle differentiation. 9 Furthermore, overexpression of FRNK in cardiomyocytes also prevents the endothelin-1 (ET-1)-induced increase in total protein/DNA, and the assembly of newly synthesized myofibrillar proteins into sarcomeres. 10 These findings suggest that FAK is required for the normal assembly of sarcomeres in response to both biomechanical and neurohormonal stimuli that induce cardiomyocyte hypertrophy. FAK serves both catalytic and scaffolding functions during biomechanical and neurohormonal signalling. FAK contains a central catalytic domain flanked by large N-and C-terminal non-catalytic domains. The C-terminal region encodes its focal adhesion targeting (FAT) domain, as well as proline-rich regions involved in protein-protein interactions. The Cterminal domain also contains several serine and tyrosine phosphorylation sites, whose phosphorylations differ depending on cell type. Tyrosine phosphorylations at Y861 and Y925 are rapidly induced in cultured rat cardiomyocytes upon stimulation with hypertrophic agonists, leading to subsequent phosphotyrosine-dependent interactions with other signalling proteins such as Src, p130Cas, and Grb2. FAK also contains four serine phosphorylation sites within its C-terminal domain (S722, S843, S846, and S910). 11 These serine residues are in close proximity to protein-protein interaction sites, such as the binding site for p130Cas. 12 The FAT domain interacts with paxillin and talin, which is responsible for targeting FAK to newly formed and existing focal adhesion complexes and for promoting downstream signalling. 13 Very little is known about the role of FAK serine phosphorylation in cardiomyocytes, but one report indicates that FAK serine phosphorylation increases dramatically in hypertensive rats, with different sites of phosphorylation appearing to regulate FAK subcellular localization. 14 The objectives of the present study were to (i) characterize FAK serine phosphorylation in cultured NRVM, in non-failing human LV myocardium, and in myocardium obtained from patients with endstage DCM; (ii) identify the responsible signalling pathways; and (3) determine its functional significance during hypertrophic signalling. Data are presented to indicate that FAK-S910 phosphorylation appears to be an important event in cell spreading and sarcomere reorganization. Furthermore, FAK is serine-phosphorylated in nonfailing, human LV tissue, but its phosphorylation is dramatically reduced in end-stage DCM, perhaps contributing to the sarcomere disorganization observed in these failing hearts.
Methods

Reagents
A detailed description of the reagents used in this study is provided in the Supplementary material online.
Neonatal rat ventricular myocyte isolation and culture
Animals used in these experiments were handled in accordance with the Guiding Principles in the Care and Use of Laboratory Animals, published by the US National Institutes of Health and approved by the American Physiological Society. Two-day old Sprague -Dawley rats were subjected to hypothermic cardiac arrest, followed by decapitation into liquid N 2 . Following removal of the heart, neonatal rat ventricular myocytes (NRVM) were isolated by collagenase digestion as previously described, 10 with additional details provided in the Supplementary material online.
Site-directed mutagenesis
3xFLAG-tagged wild-type (WT) FAK cDNA was kindly provided by Dr Joseph C. Loftus, Mayo Clinic Arizona. A serine-910 to alanine (S910A) mutation was created with the USB Change-ITTM Multiple Mutation SiteDirected Mutagenesis Kit (Santa Clara, CA, USA). The primer used for mutagenesis was: 5 ′ -/phos/CTT-CAG-CCC-CAG-GAA-ATC-GCC-CCC-CCT-CCC-ACT-GCC-AAC-3 ′ for S910A, where the underline represents the mutated bases. The mutation within FAK cDNA was confirmed by DNA sequencing.
Adenoviral constructs
A detailed description of the adenoviruses used in these experiments is provided in the Supplementary material online.
Co-immunoprecipitation, SDS-PAGE, and western blotting
For co-immunoprecipitation, cells were lysed with non-denaturing lysis buffer and used to co-immunoprecipitate FLAG-tagged FAK and paxillin, as described in detail in the Supplementary material online. For SDS -PAGE and western blotting, NRVM and human LV tissue samples ( 100 mg wet weight) were sonicated in denaturing lysis buffer. Equal amounts of extracted cellular proteins (50 -75 mg) were separated by SDS -PAGE and western blotting, as described in detail in the Supplementary material online.
2.6 Total internal reflection fluorescence microscopy and fluorescence recovery after photobleaching NRVM grown on four-well, borosilicate glass-bottomed chamber slides coated with fibronectin were infected (10 MOI, 24 h) with Adv-WT-FAK or Adv-S910A-FAK, and then infected with Adv-GFP-paxillin (10 MOI) for an additional 24 h. GFP-paxillin was imaged within costameres located at the cell membrane-substratum interface using an inverted total internal reflection fluorescence (TIRF) microscope and subjected to fluorescence recovery after photobleaching (FRAP). Methodological details are provided in the Supplementary material online. Data were fit to the following single-exponential function:
where F/F 0 was the normalized fluorescence intensity, Y 0 the best-fitting value for F/F 0 at t ¼ 0 (i.e. immediately after the flash), and k FRAP was the first-order rate constant (s
21
) describing the rate of rise in F/F 0 . Half-life (t 1/2 , s) was derived from k FRAP as: 2.7 Immunofluorescent microscopy NRVM were infected (10 MOI, 24 h) with Adv-WT-FAK or Adv-S910A-FAK and then stimulated with ET-1 (100 nM) for 48 h. Cells were fixed, permeabilized, and stained for FLAG and rhodamine phalloidin as described in the Supplementary material online.
Cell surface area measurements
NRVM were infected (10 MOI, 24 h) with Adv-WT-FAK or Adv-S910A-FAK and then treated with ET-1 100 nM for 48 h. Live cells were then dye-loaded with BCECF-AM, with details provided in the Supplementary material online.
Left ventricular tissue from non-failing and failing human hearts
Samples of LV tissue were obtained from Loyola University Medical Center's (LUMC's) Cardiovascular Institute Tissue Repository and from the Gift of Hope Organ and Tissue Donor Network. The investigation conformed to the principles outlined in the Declaration of Helsinki. A detailed protocol and informed consent document were reviewed by LUMC's Institutional Review Board prior to tissue procurement. Following informed consent, explanted human LV tissue was obtained from patients undergoing heart transplantation for non-ischaemic, DCM. Tissue samples were quick-frozen in liquid N 2 in the operating room and stored at 2808C. Following informed consent from organ donor family members, donor hearts judged unsuitable for cardiac transplantation were stored in cardioplegic solution on ice and were delivered within 4 h of cardiac extirpation by the Gift of Hope Organ and Tissue Donor Network. Tissue samples were then quickly frozen in liquid N 2 and stored at 2808C.
Data analysis
Results were expressed as means + SEM. Normality was assessed using the Kolmogorov -Smirnov test, and homogeneity of variance was assessed using Levene's test. Data were compared by one-way ANOVA or one-way ANOVA on Ranks, followed by the Dunnett' test or StudentNewman-Keuls test (multiple groups); or unpaired t-test or Wilcoxin's rank-sum test (two groups), where appropriate. Differences among means were considered significant at P , 0.05. Data were analysed using the SigmaStat Statistical Software Package, Ver. 3.11 (Jandel Scientific, San Rafael, CA, USA).
Results
Hypertrophic agonists induce FAK serine phosphorylation in NRVM
FAK serine phosphorylation was detectable under basal conditions at all four serine residues examined. Stimulation of cells with AngII, insulin-like growth factor-1 (IGF-1), ET-1, and phenylephrine (PE) (all at concentrations known to induce NRVM hypertrophy 10,15 -17 ) all increased FAK-S910 phosphorylation over time (5-30 min), with ET-1 being the most potent ( Figure 1A and B). In contrast, S722 was constitutively phosphorylated, and S732 and S843 phosphorylation were only modestly increased in response to ET-1 ( Figure 1 ) and other agonists (data not shown). The time-course, dose-response, and ET A R dependency of ET-1-induced FAK-S910 phosphorylation were similar to those of FAK-Y925 phosphorylation, but occurred later than FAK-Y397 autophosphorylation (see Supplementary material online, Figures S1 -S3 for further details). Therefore, we focused on the signalling pathways and functional significance of FAK-S910 phosphorylation in subsequent experiments.
PKC activation is necessary to induce FAK-S910 phosphorylation
NRVM express both classical and novel PKC isoenzymes, including PKCa, PKCd, and PKC1, and PKC activation is an important downstream effector of ET A R stimulation. 18 Therefore, PKC inhibitors were used to determine whether ET-1-induced PKC activation was necessary for FAK-S910 phosphorylation. As seen in Figure 1C , the non-selective PKC inhibitor GF102903X (GFX; 10 mM; 1 h pretreatment) significantly reduced but did not eliminate FAK-S910 phosphorylation. In contrast, the classical PKC inhibitor Gö 6983 (Gö; 10 mM, 1 h pre-treatment) was ineffective, suggesting that a Ca 2+ -independent, rather than a Ca 2+ -dependent PKC was required. In support of this observation, the PKCd-selective inhibitor rottlerin (Rot; 10-20 mM, 1 h pre-treatment) also reduced FAK-S910 phosphorylation to approximately the same extent as GFX. None of the small-molecule inhibitors alone increased FAK-S910 phosphorylation.
PKCd is the PKC isoenzyme involved in FAK-S910 phosphorylation
To further support the PKC inhibitor studies, adenoviral-mediated overexpression of dominant-negative (dn) PKCa, PKC1, and PKCd were used to block ET-1-induced FAK-S910 phosphorylation. As seen in Figure 1D , both dnPKCa and dnPKCd, but not dnPKC1, demonstrated inhibitory activity. The dnPKCa data were somewhat surprising, as the classical PKC inhibitor Gö was ineffective ( Figure 1C ). However, dnPKCa may not be entirely specific for PKCa inhibition, 19, 20 perhaps by interfering with the activation of other PKC isoenzymes. Additional evidence demonstrating that PKCd is both necessary and sufficient to induce FAK-S910 phosphorylation is provided in the Supplementary material online, Figures S4 and S5.
ET-1 activates the ERK cascade and phosphorylates FAK-S910 via Raf-1
Hunger-Glaser et al. 21, 22 demonstrated that stimulation of Swiss-3T3 cells with bombesin, lysophosphatidic acid, and epidermal growth factor promoted a striking increase in FAK-S910 phosphorylation in a PKC-and ERK1/2-dependent manner. Therefore, we next examined the time course of ERK1/2 activation and FAK-S910 phosphorylation in response to ET-1 (100 nM; 0-60 min). As seen in Figure 2A , ERK1/2 phosphorylation increased approximately six-fold within 5 min of ET-1 stimulation. ERK1/2 activation preceded the peak of FAK-S910 phosphorylation, which occurred at 30-90 min. ET-1-induced ERK1/2 activation was partially dependent on PKCd, as dnPKCd overexpression blocked ERK1/2 phosphorylation over the same time period ( Figure 2B ). ET-1-induced ERK1/2 and FAK-S910 phosphorylation were also blocked by two different inhibitors of MEK1/2 (i.e. PD98059 and U0126), the upstream regulators of ERK1/2 ( Figure 2C ). In contrast, SB203580, a highly specific p38 MAPK inhibitor, was without effect. The involvement of Raf-1, an upstream regulator of the ERK cascade in cardiomyocytes, was examined by adenoviral overexpression of dnRaf-1; 23 and by pharmacological inhibition with sorafenib (1-10 mM; 1 h pre-treatment). As seen in Figure 2D and Supplementary material online, Figure S6 , both approaches reduced ERK1/2 and FAK-S910 phosphorylation in response to ET-1 stimulation. Of note, ET-1-induced ERK1/2 activation was not dependent on FAK kinase activity (see Supplementary material online, Figure S7 for further details). 
Src is also involved in ET-1-induced FAK-S910 phosphorylation
When NRVM were treated with GFX ( Figure 1C) , Rot ( Figure 1C ), or dnPKCd ( Figure 1D ), ET-1-induced FAK-S910 phosphorylation was only reduced by 50%, suggesting that other signalling pathways might also be involved. ET-1 also stimulates Src family kinases (SFKs) and is important for ET-1-induced cardiomyocyte hypertrophy. 24 Therefore, to investigate whether SFKs were also involved, the SFK-specific inhibitor PP2, along with its inactive analogue PP3, was used. NRVM were pre-treated (1 h) with PP2 (5-25 mM) or PP3 (25 mM) and then stimulated with ET-1 (100 nM; 30 min). ET-1-induced FAK-S910 phosphorylation was dosedependently reduced by PP2, but not PP3 ( Figure 3A ). To confirm these inhibitor studies, we used adenoviral-mediated overexpression of dnSrc (10-50 MOI; Figure 3B ), which also significantly reduced ET-1-induced FAK-S910 phosphorylation, suggesting that Src was the specific SFK. As further evidence for the involvement of two parallel signalling pathways, we noted that neither PP2 nor Rot alone was sufficient to eliminate FAK-S910 phosphorylation. However, when NRVM were pre-treated with both Rot and PP2, the inhibitor combination completely blocked ET-1-induced FAK-S910 phosphorylation ( Figure 3C ). 
Src regulates FAK-S910 phosphorylation through MEK5/ERK5
ET-1-induced ERK1/2 phosphorylation was only partially inhibited by overexpression of dnSrc ( Figure 3D ) and was not significantly affected by PP2 (see Supplementary material online, Figure S8 ), suggesting that Src mediates downstream FAK-S910 phosphorylation by activation of serine protein kinase(s) other than ERK1/2. Villa-Moruzzi 25 demonstrated that stimulation of Swiss-3T3 cells with PMA induced FAK-S910 phosphorylation via activation of ERK5. Furthermore, Src was involved in ERK5 activation in other cell types. 26 Therefore, we examined the time course of ERK5 activation in response to ET-1 (100 nM; 0-60 min), and compared it with the time course of FAK-S910 phosphorylation. As seen in Figure 4A , ERK5 phosphorylation increased significantly within 5 min of ET-1 stimulation and preceded the peak of FAK-S910 phosphorylation, which occurred at 30-90 min. Next, we used adenoviral-mediated overexpression of dnERK5 (10-50 MOI), which dose-dependently reduced FAK-S910 phosphorylation ( Figure 4B ). Conversely, adenoviral-mediated overexpression of caMEK5 (the upstream activator of ERK5) was sufficient to induce FAK-S910 phosphorylation (see Supplementary material online, Figure S9A ). Of note, ET-1-induced ERK5 activity was also partially dependent on Src, as overexpression of dnSrc ( Figure 4C ) or pretreatment with PP2 (see Supplementary material online, Figure S9B ) both blocked ET-1-induced ERK5 phosphorylation. Overexpression of dnPKCd also reduced ET-1-induced ERK5 activation ( Figure 4D) . Overall, these results indicated that ET-1-induced FAK-S910 phosphorylation involved both Src MEK5 ERK5 and PKCd MEK5 ERK5 signalling pathways. 
FAK-S910 phosphorylation regulates the interaction of FAK with paxillin
To determine whether FAK-S910 phosphorylation affects the FAKpaxillin interaction, we used TIRF microscopy and FRAP analysis to examine paxillin-binding kinetics at costameres located at the cell membrane-substratum interface. Adenoviral overexpression of an FLAG-tagged, non-phosphorylatable FAK mutant (S910A-FAK) significantly reduced the k FRAP of GFP-paxillin, when compared with NRVM expressing FLAG-tagged WT-FAK ( Figure 5A ). Thus, rendering FAK non-phosphorylatable at S910 increased the half-life of GFP-paxillin within costameres (5.4 + 0.0.3 vs. 6.6 + 0.3 s for WT-FAK-vs. S910A-FAK-expressing cells; P ¼ 0.006). Thus, overexpression of S910A-FAK reduced the dynamic exchange of GFP-paxillin and increased its interaction with other focal adhesion proteins within cardiomyocyte costameres. These altered paxillinbinding kinetics resulted in increased steady-state interaction of endogenous paxillin with S910A-FAK, as determined by co-immunoprecipitation and western blotting with anti-FLAG or anti-paxillin antibodies ( Figure 5B ).
FAK-S910 phosphorylation is important for NRVM sarcomere assembly and spreading
Increased cell spreading, cytoskeletal reorganization, and sarcomere assembly are all characteristics of cardiomyocyte hypertrophy. 27 Therefore, to determine the effect of FAK-S910 phosphorylation on these parameters, NRVM were infected with Adv-WT-FAK or Adv-S910A-FAK (10 MOI, 24 h) and then stimulated with ET-1 (100 nM; 48 h). ET-1-induced sarcomeric organization was first examined by double-label epifluorescent microscopy ( Figure 5C ). Although there was no apparent difference in sarcomeric organization in unstimulated cells, ET-1 stimulation induced an obvious increase in sarcomere assembly in cells expressing WT-FAK, but not in cardiomyocytes expressing S910A-FAK. These qualitative changes in sarcomeric organization were associated with a significant increase in the cell surface area of ET-1-treated WT-FAK-expressing cells, but there was no increase in the cell surface area of ET-1-stimulated cells expressing S910A-FAK ( Figure 5D ).
FAK is serine-phosphorylated in human hearts
Lastly, we examined the phosphorylation status of FAK serine residues in non-failing human LV tissue and in LV tissue from patients undergoing cardiac transplantation for end-stage DCM. As seen in Figure 6A , there was no significant difference in the amount of total FAK relative to total protein in tissue homogenates of both groups. FAK was serine-phosphorylated in non-failing LV at all four residues examined (S722, S732, S843, and S910). Interestingly, FAK-S843 phosphorylation was reduced by 63% (P ¼ 0.175), and FAK-S910 phosphorylation was reduced by 91% (P , 0.05) in DCM when compared with non-failing, control hearts. These reductions in FAK serine phosphorylation were not associated with any significant change in ERK1/2 expression or phosphorylation (data not shown). In contrast, LV ERK5 expression was significantly reduced in patients with DCM undergoing heart transplantation, when compared with control, non-failing LV tissue samples ( Figure 6B ).
Discussion
Previous studies addressing FAK's role in cardiomyocyte hypertrophy have focused on its tyrosine phosphorylation and kinase activity. 10, 17, 28, 29 However, it has been known for some time that FAK also undergoes serine phosphorylation at multiple residues within its C-terminus. For instance, Yi et al. 30 showed that FAK-S722 and FAK-S910 phosphorylation were significantly increased in LV tissue and isolated cardiomyocytes of hypertensive heart failure rats. Despite this initial observation, however, no studies have addressed the responsible signalling pathways and functional significance of FAK serine phosphorylation in cardiomyocytes. In this report, we demonstrate that FAK is serine-phosphorylated in non- failing and failing human hearts. Furthermore, FAK serine phosphorylation is regulated by hypertrophic factors and plays a critical role in cell spreading and new sarcomere formation during cardiomyocyte hypertrophy. We found that FAK-S910 phosphorylation was markedly reduced in DCM patients undergoing heart transplantation. These results suggested an important role for FAK serine phosphorylation in the pathological response of cardiomyocytes during end-stage heart failure. DCM is characterized by aberrant signal transduction, reduced contractile function, and cytoskeletal disarray, 31 which was mimicked during hypertrophic stimulation of NRVM by overexpression of a non-phosphorylatable, S910A-FAK mutant. It is interesting to speculate that the failure to normally serine-phosphorylate FAK in DCM may have contributed to the cardiomyocyte structural abnormalities and reduced contractile function in these critically ill patients.
We also demonstrated that neurohormonal agonists increase FAK-S910 phosphorylation, both through G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases. Our results are similar to studies conducted in Swiss-3T3 fibroblasts. 21, 22 In the case of ET-1, our data suggest that the ET A R is the responsible GPCR, which is consistent with studies, indicating that this receptor subclass is also responsible for other aspects of ET-1-induced NRVM hypertrophy. 32 Of note, ET-1 stimulation caused the rapid, ET A R-mediated translocation of PKCd and PKC1 (but not PKCa), and subsequent stimulation of the Raf-1 -MEK1/2-ERK1/2 cascade. 16, 33 However, ET-1-induced S910 phosphorylation was only reduced by 50% by PKCd inhibition, suggesting that other signalling pathways activated by the ET A R are also operative. Our data indicating that PP2 and dnSrc also reduced, but did not eliminate FAK-S910 phosphorylation, suggested the existence of a parallel signalling pathway that involved SFKs. In this regard, several studies have provided evidence for GPCR-dependent activation of SFKs, and SFK activation is necessary for induction of atrial natriuretic factor transcription, a marker of NRVM hypertrophy. Indeed, the major SFK isoforms in NRVM are Src, Fyn, and Yes, and all three kinases are activated by ET-1. 24 Our results indicate that SFK-dependent FAK-S910 phosphorylation is in part mediated by MEK5 and ERK5, and that PKCd is also involved in this limb of the signalling pathways. Of note, VillaMoruzzi 25 demonstrated that ERK5 regulated FAK-S910 phosphorylation in Swiss-3T3 fibroblasts, and Src has been found to regulate ERK5 activation in other cell types. 26 However, we now demonstrate that both SFKs and PKCd are upstream regulators of the MEK5-ERK5 signalling cascade in NRVM. Despite these observations, the mechanisms responsible for Src activation by ET-1 are still not clear. Src can directly phosphorylate PKCd and alter its substrate specificity in NRVM and other cell types. 34 -37 Conversely, PKCd has been shown to regulate Src activity. 38, 39 Thus, the interaction between Src and PKCd in regulating ET-1-induced FAK-S910 phosphorylation may be mediated by the substantial, bi-directional crosstalk between Src and PKCd, and may also be responsible for the simultaneous activation of ERK1/2 and ERK5.
Our results indicate that both ERK1/2 and ERK5 can phosphorylate FAK at S910, and FAK-S910 phosphorylation appears necessary for new costamere formation during cardiomyocyte remodelling. A schematic depicting the dual signalling pathways is depicted in Figure 6C . Thus, we speculate that in addition to their roles in regulating gene transcription, ERK1/2 and ERK5 regulate costamere formation that is required for the addition of new sarcomeres, both in series and in parallel. Of note, these two distinct signalling pathways have also been implicated in regulating length vs. width remodelling of cardiomyocytes during ageing or stress stimulation. 40 
